Rucaparib (BioDeep_00000015154)
Main id: BioDeep_00000183055
代谢物信息卡片
Rucaparib
化学式: C19H18FN3O (323.14338300000003)
中文名称: 瑞卡帕布
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CNCC1=CC=C(C=C1)C2=C3CCNC(=O)C4=C3C(=CC(=C4)F)N2
InChI: InChI=1S/C19H18FN3O/c1-21-10-11-2-4-12(5-3-11)18-14-6-7-22-19(24)15-8-13(20)9-16(23-18)17(14)15/h2-5,8-9,21,23H,6-7,10H2,1H3,(H,22,24)
描述信息
L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01X - Other antineoplastic agents > L01XK - Poly (adp-ribose) polymerase (parp) inhibitors
C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C62554 - Poly (ADP-Ribose) Polymerase Inhibitor
D000970 - Antineoplastic Agents > D000067856 - Poly(ADP-ribose) Polymerase Inhibitors
D004791 - Enzyme Inhibitors
C471 - Enzyme Inhibitor
同义名列表
1 个代谢物同义名
数据库引用编号
8 个数据库交叉引用编号
- ChEBI: CHEBI:134689
- ChEBI: CHEBI:94311
- KEGG: C74459
- KEGGdrug: D10079
- PubChem: 9931954
- DrugBank: DB12332
- ChEMBL: CHEMBL1173055
- CAS: 283173-50-2
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Brieuc Sautois, Andrea Loehr, Simon P Watkins, Hélène Schroeder, Wassim Abida. A Case Study of Clinical Response to Rucaparib in a Patient with Metastatic Castration-Resistant Prostate Cancer and a RAD51B Alteration.
Current oncology (Toronto, Ont.).
2022 06; 29(6):4178-4184. doi:
10.3390/curroncol29060333. [PMID: 35735442] - Andrea Loehr, Akash Patnaik, David Campbell, Jeremy Shapiro, Alan H Bryce, Ray McDermott, Brieuc Sautois, Nicholas J Vogelzang, Richard M Bambury, Eric Voog, Jingsong Zhang, Josep M Piulats, Arif Hussain, Charles J Ryan, Axel S Merseburger, Gedske Daugaard, Axel Heidenreich, Karim Fizazi, Celestia S Higano, Laurence E Krieger, Cora N Sternberg, Simon P Watkins, Darrin Despain, Andrew D Simmons, Melanie Dowson, Tony Golsorkhi, Simon Chowdhury, Wassim Abida. Response to Rucaparib in BRCA-Mutant Metastatic Castration-Resistant Prostate Cancer Identified by Genomic Testing in the TRITON2 Study.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2021 12; 27(24):6677-6686. doi:
10.1158/1078-0432.ccr-21-2199. [PMID: 34598946] - Mingxiang Liao, Krzysztof G Jeziorski, Monika Tomaszewska-Kiecana, István Láng, Marek Jasiówka, Viera Skarbová, Piotr Centkowski, Rodryg Ramlau, Maria Górnaś, John Lee, Sarah Edwards, Jenn Habeck, Eileen Nash, Nikolay Grechko, Jim J Xiao. A phase 1, open-label, drug-drug interaction study of rucaparib with rosuvastatin and oral contraceptives in patients with advanced solid tumors.
Cancer chemotherapy and pharmacology.
2021 11; 88(5):887-897. doi:
10.1007/s00280-021-04338-7. [PMID: 34370076] - Nikolay Grechko, Viera Skarbova, Monika Tomaszewska-Kiecana, Rodryg Ramlau, Piotr Centkowski, Yvette Drew, Rafal Dziadziuszko, Milada Zemanova, Jeri Beltman, Eileen Nash, Jenn Habeck, Mingxiang Liao, Jim Xiao. Pharmacokinetics and safety of rucaparib in patients with advanced solid tumors and hepatic impairment.
Cancer chemotherapy and pharmacology.
2021 08; 88(2):259-270. doi:
10.1007/s00280-021-04278-2. [PMID: 33909097] - Domenica Lorusso, Giuseppa Maltese, Ilaria Sabatucci, Sara Cresta, Cristina Matteo, Tommaso Ceruti, Maurizio D'Incalci, Massimo Zucchetti, Francesco Raspagliesi, Cristina Sonetto, Valentina Sinno, Dominique Ronzulli, Serena Giolitto, Filippo de Braud. Phase I Study of Rucaparib in Combination with Bevacizumab in Ovarian Cancer Patients: Maximum Tolerated Dose and Pharmacokinetic Profile.
Targeted oncology.
2021 01; 16(1):59-68. doi:
10.1007/s11523-020-00780-4. [PMID: 33369704] - Ashish Shah, Ghanshyam Parmar, Avinash Kumar Seth. In Silico Discovery of Novel Flavonoids as Poly ADP Ribose Polymerase (PARP) Inhibitors.
Current computer-aided drug design.
2021; 17(3):344-350. doi:
10.2174/1573409916666200408082858. [PMID: 32268868] - David J VanderWeele, Maha Hussain. PARP inhibitors in prostate cancer: practical guidance for busy clinicians.
Clinical advances in hematology & oncology : H&O.
2020 Dec; 18(12):808-815. doi:
NULL. [PMID: 33406057] - Mingxiang Liao, Sarah Jaw-Tsai, Jeri Beltman, Andrew D Simmons, Thomas C Harding, Jim J Xiao. Evaluation of in vitro absorption, distribution, metabolism, and excretion and assessment of drug-drug interaction of rucaparib, an orally potent poly(ADP-ribose) polymerase inhibitor.
Xenobiotica; the fate of foreign compounds in biological systems.
2020 Sep; 50(9):1032-1042. doi:
10.1080/00498254.2020.1737759. [PMID: 32129697] - Mingxiang Liao, Simon Watkins, Eileen Nash, Jeff Isaacson, Jeff Etter, Jeri Beltman, Rong Fan, Li Shen, Abdul Mutlib, Vendel Kemeny, Zsuzsanna Pápai, Pascal van Tilburg, Jim J Xiao. Evaluation of absorption, distribution, metabolism, and excretion of [14C]-rucaparib, a poly(ADP-ribose) polymerase inhibitor, in patients with advanced solid tumors.
Investigational new drugs.
2020 06; 38(3):765-775. doi:
10.1007/s10637-019-00815-2. [PMID: 31250355] - Yonghe Wang, Yunxia Zheng, Yuchen Hao. Rucaparip (Rubraca®) induces necrosis via upregulating the expression of RIP1 and RIP3 in ovarian cancer cells.
Die Pharmazie.
2020 06; 75(6):242-245. doi:
10.1691/ph.2020.9827. [PMID: 32539918] - Amanda J Boyle, Ping-Jiang Cao, Zhongli Cai, Conrad Chan, David W Hedley, Raymond M Reilly. Radioimmunotherapy of human pancreatic cancer xenografts in NOD-scid mice with [64Cu]Cu-NOTA-panitumumab F(ab')2 alone or combined with radiosensitizing gemcitabine and the PARP inhibitor, rucaparib.
Nuclear medicine and biology.
2020 May; 84-85(?):46-54. doi:
10.1016/j.nucmedbio.2020.02.001. [PMID: 32062317] - M A C Bruin, N de Vries, L Lucas, H Rosing, A D R Huitema, J H Beijnen. Development and validation of an integrated LC-MS/MS assay for therapeutic drug monitoring of five PARP-inhibitors.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2020 Feb; 1138(?):121925. doi:
10.1016/j.jchromb.2019.121925. [PMID: 31915109] - Graziela Zibetti Dal Molin, Shannon Neville Westin, Pavlos Msaouel, Larissa M Gomes, Andrea Dickens, Robert L Coleman. Discrepancy in calculated and measured glomerular filtration rates in patients treated with PARP inhibitors.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.
2020 01; 30(1):89-93. doi:
10.1136/ijgc-2019-000714. [PMID: 31792084] - Kevin K Lin, Maria I Harrell, Amit M Oza, Ana Oaknin, Isabelle Ray-Coquard, Anna V Tinker, Elena Helman, Marc R Radke, Carmen Say, Lan-Thanh Vo, Elaina Mann, Jeffrey D Isaacson, Lara Maloney, David M O'Malley, Setsuko K Chambers, Scott H Kaufmann, Clare L Scott, Gottfried E Konecny, Robert L Coleman, James X Sun, Heidi Giordano, James D Brenton, Thomas C Harding, Iain A McNeish, Elizabeth M Swisher. BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma.
Cancer discovery.
2019 02; 9(2):210-219. doi:
10.1158/2159-8290.cd-18-0715. [PMID: 30425037] - Geoffrey I Shapiro, Rebecca S Kristeleit, Howard A Burris, Patricia LoRusso, Manish R Patel, Yvette Drew, Heidi Giordano, Lara Maloney, Simon Watkins, Sandra Goble, Sarah Jaw-Tsai, Jim J Xiao. Pharmacokinetic Study of Rucaparib in Patients With Advanced Solid Tumors.
Clinical pharmacology in drug development.
2019 01; 8(1):107-118. doi:
10.1002/cpdd.575. [PMID: 29799676] - Karen E Parrish, Ling Cen, James Murray, David Calligaris, Sani Kizilbash, Rajendar K Mittapalli, Brett L Carlson, Mark A Schroeder, Julieann Sludden, Alan V Boddy, Nathalie Y R Agar, Nicola J Curtin, William F Elmquist, Jann N Sarkaria. Efficacy of PARP Inhibitor Rucaparib in Orthotopic Glioblastoma Xenografts Is Limited by Ineffective Drug Penetration into the Central Nervous System.
Molecular cancer therapeutics.
2015 Dec; 14(12):2735-43. doi:
10.1158/1535-7163.mct-15-0553. [PMID: 26438157] - Diane D Wang, Chunze Li, Wan Sun, Shuzhong Zhang, David R Shalinsky, Kenneth A Kern, Nicola J Curtin, Wai-Johnn Sam, Tanya R Kirkpatrick, Ruth Plummer. PARP activity in peripheral blood lymphocytes as a predictive biomarker for PARP inhibition in tumor tissues - A population pharmacokinetic/pharmacodynamic analysis of rucaparib.
Clinical pharmacology in drug development.
2015 03; 4(2):89-98. doi:
10.1002/cpdd.176. [PMID: 27128213] - Cian M McCrudden, Martin G O'Rourke, Kim E Cherry, Hiu-Fung Yuen, Declan O'Rourke, Muhammad Babur, Brian A Telfer, Huw D Thomas, Patrick Keane, Thiagarajan Nambirajan, Chris Hagan, Joe M O'Sullivan, Chris Shaw, Kaye J Williams, Nicola J Curtin, David G Hirst, Tracy Robson. Vasoactivity of rucaparib, a PARP-1 inhibitor, is a complex process that involves myosin light chain kinase, P2 receptors, and PARP itself.
PloS one.
2015; 10(2):e0118187. doi:
10.1371/journal.pone.0118187. [PMID: 25689628] - Selvi Durmus, Rolf W Sparidans, Anita van Esch, Els Wagenaar, Jos H Beijnen, Alfred H Schinkel. Breast cancer resistance protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1) restrict oral availability and brain accumulation of the PARP inhibitor rucaparib (AG-014699).
Pharmaceutical research.
2015 Jan; 32(1):37-46. doi:
10.1007/s11095-014-1442-z. [PMID: 24962512] - M Emmy M Dolman, Ilona J M den Hartog, Jan J Molenaar, Jan H M Schellens, Jos H Beijnen, Rolf W Sparidans. Liquid chromatography-tandem mass spectrometric assay for the cyclin-dependent kinase inhibitor AT7519 in mouse plasma.
Journal of pharmaceutical and biomedical analysis.
2014 Jan; 88(?):216-20. doi:
10.1016/j.jpba.2013.08.051. [PMID: 24080524] - Rolf W Sparidans, Selvi Durmus, Alfred H Schinkel, Jan H M Schellens, Jos H Beijnen. Liquid chromatography-tandem mass spectrometric assay for the PARP inhibitor rucaparib in plasma.
Journal of pharmaceutical and biomedical analysis.
2014 Jan; 88(?):626-9. doi:
10.1016/j.jpba.2013.10.016. [PMID: 24216281] - Rachel A Daniel, Agata L Rozanska, Huw D Thomas, Evan A Mulligan, Yvette Drew, Deborah J Castelbuono, Zdenek Hostomsky, E Ruth Plummer, Alan V Boddy, Deborah A Tweddle, Nicola J Curtin, Steven C Clifford. Inhibition of poly(ADP-ribose) polymerase-1 enhances temozolomide and topotecan activity against childhood neuroblastoma.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2009 Feb; 15(4):1241-9. doi:
10.1158/1078-0432.ccr-08-1095. [PMID: 19174487] - Christopher R Calabrese, Robert Almassy, Stephanie Barton, Michael A Batey, A Hilary Calvert, Stacie Canan-Koch, Barbara W Durkacz, Zdenek Hostomsky, Robert A Kumpf, Suzanne Kyle, Jianke Li, Karen Maegley, David R Newell, Elena Notarianni, Ian J Stratford, Donald Skalitzky, Huw D Thomas, Lan-Zhen Wang, Stephen E Webber, Kaye J Williams, Nicola J Curtin. Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361.
Journal of the National Cancer Institute.
2004 Jan; 96(1):56-67. doi:
10.1093/jnci/djh005. [PMID: 14709739]